Overview

Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, phase II study to evaluate the efficacy and safety of Abraxane in combination with Capecitabine in patients with metastatic colorectal cancer in the second or third line
Phase:
Phase 2
Details
Lead Sponsor:
Mt. Sinai Medical Center, Miami
Collaborator:
Celgene Corporation
Treatments:
Albumin-Bound Paclitaxel
Capecitabine
Paclitaxel